3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
275
Thoracic
34
Breast
25
Dermatologic
17
Gastrointestinal
15
Genitourinary
10
Sarcoma
9
Head & Neck
9
Endocrine
6
Lymphoid
5
Other hematologic neoplasm
3
Gynecologic
3
NET
1
Myeloid
1
Conditions
Neuroendocrine Tumors
69
Gastro-enteropancreatic neuroendocrine tumor
8
Pheochromocytoma
7
Carcinoma, Neuroendocrine
7
Carcinoid Tumor
7
Adenoma, Islet Cell
7
Paraganglioma
6
Neoplasms
5
Melanoma
5
Breast Neoplasms
5
Thyroid Neoplasms
4
Sarcoma
4
Pancreatic Neoplasms
4
Neuroblastoma
4
Neoplasm Metastasis
4
Carcinoma
4
Serotonin Syndrome
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neuroectodermal Tumors, Primitive
3
Mesothelioma
3
Meningioma
3
Liver Neoplasms
3
Colonic Neoplasms
3
Cholangiocarcinoma
3
Central Nervous System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Anus Neoplasms
3
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
NET
×
90 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA